Additional studies are in progress to further investigate the metabolic switch in GSCs upon treatment with LDH-A inhibitors in both normoxic and hypoxic conditions, as well as the putative use of these compounds in combination with conventional GBM chemotherapeutics. This evidence concerns the gene LDHA and glioblastoma.